Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Pharmacology & Therapeutics|June 21, 2020
Diagnosis and management of systemic light chain AL amyloidosisDivaya Bhutani, Suzanne LentzschBlood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myelomaDivaya Bhutani, Jeffrey A ZonderExpert Opinion on Biological Therapy|January 5, 2013
Monoclonal antibodies in oncology therapeutics: present and future indicationsDivaya Bhutani, Ulka N VaishampayanCurrent Opinion in Hematology|October 13, 2015
Activated T cells armed with bispecific antibodies kill tumor targetsDivaya Bhutani, Lawrence G LumClinical Lymphoma, Myeloma & Leukemia|July 3, 2019
Fibril-directed Therapies in Systemic Light Chain AL AmyloidosisDivaya Bhutani, Siyang Leng, Suzanne LentzschHematology. American Society of Hematology. Education Program|December 5, 2025
Endless possibilities and how to exploit them? What is the optimal treatment sequence?Rajshekhar Chakraborty, Divaya Bhutani, Suzanne LentzschHematology. American Society of Hematology. Education Program|December 7, 2019
How I treat a refractory myeloma patient who is not eligible for a clinical trialSiyang Leng, Divaya Bhutani, Suzanne LentzschBritish Journal of Haematology|May 20, 2022
How do we manage t(11;14) plasma cell disorders with venetoclax?Rajshekhar Chakraborty, Divaya Bhutani, Suzanne LentzschClinical Lymphoma, Myeloma & Leukemia|August 3, 2020
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma PatientsVikram Premkumar, Divaya Bhutani, Suzanne LentzschEjhaem|July 18, 2022
Use of daratumumab in high risk multiple myeloma: A meta-analysisVikram Premkumar, Samuel Pan, Suzanne Lentzsch, et al.Pageof 7